- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02263222
A Feasibility Dose-escalating Study of MDT-10013 for Acute Postoperative Pain Following Total Knee Arthroplasty
June 6, 2016 updated by: Medtronic Spinal and Biologics
A Feasibility Dose-escalating Study to Evaluate the Tolerability and Systemic Exposure of MDT-10013 Plus Routine Care in the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty
This is an open-label dose-escalating study to evaluate the tolerability and systemic exposure of MDT-10013 in men and women at least 18 years of age who are undergoing primary unilateral TKA.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35216
- Achieve Clinical Research, LLC
-
-
Florida
-
Deland, Florida, United States, 32720
- Florida Research Associates, LLC
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16602
- Clinical Research Department, University of Orthopedics Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Is male or female at least 18 years of age
- Has a body mass index from 18 kg/m2 to 40 kg/m2
- Is scheduled to undergo standard primary (first-time) unilateral TKA surgery (due to osteoarthritis) with or without patellar resurfacing. Standard conventional instrumentation and cemented components must be used and the surgery shall be conducted under spinal anesthesia.
Females must meet the following criteria:
- Is of nonchildbearing potential, defined as any woman who has undergone surgical sterilization or is more than 2 years postmenopausal
- If of childbearing potential, may be enrolled if pregnancy test results are negative at Screening and if she is routinely using an effective method of birth control with a low failure rate (i.e., hormonal contraception, intrauterine device, condoms in combination with a spermicidal cream, or total sexual abstinence).
- May not be pregnant or lactating
- Has read, understood, and signed the informed consent before study entry
- Is mentally competent, reliable, and cooperative to undergo all visits and procedures scheduled in the study protocol and to record the required information.
Exclusion Criteria:
- Has had previous spinal surgery or other contraindications that preclude use of spinal anesthesia or is not indicated for surgery because of an inflammatory process or risk of infection or delayed wound healing (e.g., autoimmune disorder)
- Is scheduled to undergo a concurrent surgical procedure (e.g., bilateral TKA)
- Has a concurrent painful condition or surgery that may require analgesic treatment (such as a nonsteroidal antiinflammatory drug [NSAID] or opioid) in the postsurgical period for pain not strictly related to the TKA, and that may confound postsurgical assessments
- Has a history of allergy or hypersensitivity to the components in the investigational product or to the routine care medications
- Has current orthostatic hypotension (i.e., systolic blood pressure decrease of at least 20 mmHg or diastolic blood pressure decrease of at least 10 mmHg or an increase in heart rate of 20 beats per minute within 3 minutes of standing)
- Has any clinically significant cardiovascular condition as evidenced by physical examination, medical history, and/or baseline electrocardiogram (ECG), including inadequately controlled hypertension
- Has evidence of bradycardia as shown by heart rate of <50 beats per minute via screening ECG
- In the investigator's opinion, subject is not a suitable candidate for study treatment and/or has any poorly controlled or serious medical conditions, psychiatric illnesses, or clinically significant laboratory values that the investigator suspects could compromise the subject's safety or the scientific integrity of the study (e.g., human immunodeficiency virus [HIV], hepatitis B or C [hep B, hep C])
- Has presence or history of local or systemic malignant disease in the past 5 years (history of basal cell carcinoma will be allowed)
- Has undergone prior open surgery in the affected knee
- Has impaired renal function (creatinine >1.5 times upper limit of normal)
- Has chronic liver function impairment (aspartate aminotransferase or alanine aminotransferase >3 times upper limit of normal)
- Has insulin-dependent diabetes or uncontrolled diabetes mellitus (glycosylated hemoglobin >7%)
- Has leukopenia (<3500 leukocytes/μL)
Has current treatment with any of the following medications:
- Systemic corticosteroids within 1 month of the planned surgery (intranasal/inhaled steroids are acceptable)
- Immunosuppressant therapy to treat autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, sarcoidosis, focal segmental glomerulosclerosis, Crohn's disease, Behcet's disease, pemphigus, or ulcerative colitis)
- Oral or topical products containing clonidine (e.g., Catapres®)
- Antiepileptic drugs, antipsychotics, monoamine oxidase inhibitors, lithium, or sulfonamides
- Calcium channel blocker, digoxin, or beta-adrenergic blockers
- Chronically uses opioids, defined as use on at least 20 of the last 30 days before study Screening, and is unable to refrain from opioid use within the 24 hour period before surgery
- Investigator determines subject has a known or suspected history of drug or alcohol abuse
- Recent dose adjustment or commencement of treatment with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and/or tricyclic antidepressants (use of these medications is allowed if the dose is stable for at least 8 weeks before receiving study treatment)
- Has received any other investigational drug or device within 30 days of Screening
- Experiences any surgical complication that, in the investigator's opinion, precludes implantation of MDT-10013.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MDT-10013
Subjects will receive MDT-10013.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic (PK) parameters of MDT-10013--maximum plasma concentration observed (Cmax)
Time Frame: From day 1 to day 14
|
From day 1 to day 14
|
Pharmacokinetic (PK) parameters of MDT-10013--time to maximum plasma concentration observed (tmax)
Time Frame: From day 1 to day 14
|
From day 1 to day 14
|
Pharmacokinetic (PK) parameters of MDT-10013--area under the plasma concentration versus time curve (AUC)
Time Frame: From day 1 to day 14
|
From day 1 to day 14
|
Rate of study drug/treatment-related serious adverse events (SAEs)
Time Frame: up to 3 months
|
up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summed pain intensity scores at rest
Time Frame: up to 120 hours
|
Summed pain intensity scores (calculated as a time-weighted average) by using an 11-point (0 to 10) numerical rating scale (NRS).
|
up to 120 hours
|
Summed pain intensity scores over 2 to 48 hours (SPI-48) with activity
Time Frame: up to 48 hours
|
up to 48 hours
|
|
Aggregate dosage of all opioid analgesia
Time Frame: 0 to 24 hours and 0 to 48 hours
|
0 to 24 hours and 0 to 48 hours
|
|
Total use of opioid analgesia
Time Frame: From 48 hours through Day 6/120 hours
|
From 48 hours through Day 6/120 hours
|
|
Time to first use of opioid analgesia defined as the time from Time 0 to the first use of opioid analgesia.
Time Frame: Time 0 is defined as the initiation of arthrotomy closure to the first opioid analgesia use
|
Time 0 is defined as the initiation of arthrotomy closure to the first opioid analgesia use
|
|
Subject global evaluation of study treatment
Time Frame: up to 10-14 days
|
up to 10-14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2016
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
September 30, 2014
First Submitted That Met QC Criteria
October 8, 2014
First Posted (Estimate)
October 13, 2014
Study Record Updates
Last Update Posted (Estimate)
June 7, 2016
Last Update Submitted That Met QC Criteria
June 6, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P13-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-operation Pain
-
Near East University, TurkeyCompletedthe Influence of Intra- vs Extra-abdominal Removal of Placenta | Duration of Operation | the Amount of Aspirated Fluid During the Operation | Difference Between Pre- and Post-operative CBCTurkey
-
Pamela Youde Nethersole Eastern HospitalCompletedRecurrence | Pain Score | Survival | Operation TimeHong Kong
-
University of MichiganCompleted
-
Mahidol UniversityRecruitingFasting Before OperationThailand
-
Catholic Health InitiativesTerminated
-
Università degli Studi di BresciaCompletedPerformance of Wrong Procedure (Operation)
-
Shuhui LiangRecruitingOperation | Single-balloon EnteroscopyChina
-
Universitätsklinikum Hamburg-EppendorfTerminated
-
KU LeuvenCompletedComplication of Surgical Procedure | Operation TimeBelgium
-
University Hospital, GhentCompletedColorectal Cleansing Prior OperationBelgium
Clinical Trials on MDT-10013
-
Medtronic Spinal and BiologicsCompletedPostoperative PainUnited States
-
MicroDose Therapeutx, IncCompletedRespiratory Syncytial Virus Infections | Drug SafetyUnited States
-
MicroDose Therapeutx, IncCompleted
-
Medtronic Spinal and BiologicsCompletedSciatica | Lumbosacral RadiculopathyUnited States
-
MicroDose Therapeutx, IncCompletedDrug SafetyUnited States
-
Rijnstate HospitalCompletedFrailty | Pre-operative | High-risk PatientNetherlands
-
Medtronic CardiovascularCompletedAortic Valve StenosisJapan
-
Medtronic CardiovascularCompletedAortic Valve StenosisJapan
-
Medtronic Cardiac SurgeryMedtronicActive, not recruiting
-
Nantes University HospitalUnknown